Low Prevalence of Adverse Outcomes in an 18-Month Follow-Up of Individuals With Chronic Pain Recently Certified for Medical Cannabis

BACKGROUND: Given the scarce data on adverse outcomes in people who use medical cannabis, the objective of this study was to assess the prevalence of adverse outcomes, including cannabis use disorder (CUD), opioid use disorder (OUD), hazardous alcohol use, cannabis diversion, cannabis-related injuries, and emergency room visits in individuals newly certified for medical cannabis for chronic pain in New York. METHODS: In an 18-month longitudinal cohort study, data were collected from 223 adults (mean age = 56.3 years, 54.3% female). At baseline and every 3 months, we assessed study outcomes using structured DSM-5 diagnostic interviews, standardized questionnaires, and study-specific questions. Medical and unregulated cannabis use were self-reported separately every 2 weeks via web surveys. FINDINGS: Over 18 months, 4.9% of participants met the DSM-5 criteria for CUD at 1 or more study visits, 0.9% for OUD, 6.7% for hazardous alcohol use, 4.0% for cannabis diversion, and 1.8% for cannabis-related injuries. The mean frequency of medical and unregulated cannabis use per 2-week period was 9.6 and 5.3 days, respectively, for those with CUD and 6.4 and 2.7 days, respectively, for those without CUD. No consistent patterns emerged for other adverse outcomes. CONCLUSIONS: In this cohort of adults with chronic pain newly certified for medical cannabis, adverse outcomes were infrequent during the 18-month follow-up, despite participants reporting regular use throughout the study. However, these findings should be interpreted with caution, as larger or longer term studies may detect risks not captured in this study. Continued patient education and monitoring remain important, and more research is needed to understand the long-term safety of medical cannabis use, particularly as policies continue to evolve.

Authors

Institutions

Publication Details

Journal
Substance Use &amp Addiction Journal
Published
2026-11-20
DOI
https://doi.org/10.1177/29767342261496711
Primary Topic
Cannabis and Cannabinoid Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Low Prevalence of Adverse Outcomes in an 18-Month Follow-Up of Individuals With Chronic Pain Recently Certified for Medical Cannabis

Yuval Zolotov, Chinazo O. Cunningham, Joanna L. Starrels, Deepika E. Slawek et al.
2 links
Substance Use &amp Addiction Journal
Cannabis and Cannabinoid Research
article

Low Prevalence of Adverse Outcomes in an 18-Month Follow-Up of Individuals With Chronic Pain Recently Certified for Medical Cannabis

Yuval Zolotov, Chinazo O. Cunningham, Joanna L. Starrels, Deepika E. Slawek, Julia Hope Arnsten, Jonathan Ross, FRANCES RUDNICK LEVIN, Nancy Sohler, Stephen Dahmer, Chenshu Zhang
article en

Abstract

BACKGROUND: Given the scarce data on adverse outcomes in people who use medical cannabis, the objective of this study was to assess the prevalence of adverse outcomes, including cannabis use disorder (CUD), opioid use disorder (OUD), hazardous alcohol use, cannabis diversion, cannabis-related injuries, and emergency room visits in individuals newly certified for medical cannabis for chronic pain in New York. METHODS: In an 18-month longitudinal cohort study, data were collected from 223 adults (mean age = 56.3 years, 54.3% female). At baseline and every 3 months, we assessed study outcomes using structured DSM-5 diagnostic interviews, standardized questionnaires, and study-specific questions. Medical and unregulated cannabis use were self-reported separately every 2 weeks via web surveys. FINDINGS: Over 18 months, 4.9% of participants met the DSM-5 criteria for CUD at 1 or more study visits, 0.9% for OUD, 6.7% for hazardous alcohol use, 4.0% for cannabis diversion, and 1.8% for cannabis-related injuries. The mean frequency of medical and unregulated cannabis use per 2-week period was 9.6 and 5.3 days, respectively, for those with CUD and 6.4 and 2.7 days, respectively, for those without CUD. No consistent patterns emerged for other adverse outcomes. CONCLUSIONS: In this cohort of adults with chronic pain newly certified for medical cannabis, adverse outcomes were infrequent during the 18-month follow-up, despite participants reporting regular use throughout the study. However, these findings should be interpreted with caution, as larger or longer term studies may detect risks not captured in this study. Continued patient education and monitoring remain important, and more research is needed to understand the long-term safety of medical cannabis use, particularly as policies continue to evolve.

Substance Use &amp Addiction Journal
Albert Einstein College of Medicine (US), Montefiore Medical Center (US), University of Arizona (US), City University of New York (US), Ariel University (IL), Columbia University (US)
National Institute of Mental Health, National Institute on Drug Abuse
Good health and well-being
Cannabis and Cannabinoid Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon